Search results for ERBB2

Anti-Human CD340/ERBB2/HER2 Antibody (4D5V8) (HY286107), abinScience, HY286107

Disitamab Biosimilar – Anti-ERBB2, EGFR2, CD340 mAb – Research Grade, ProteoGenix, PX-TA1574

Description of Disitamab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb - Research Grade Disitamab Biosimilar: A Revolutionary Antibody Targeting ERBB2, EGFR2, and CD340 Disitamab Biosimilar, also known as Anti-ERBB2, EGFR2, CD340 mAb, is a highly potent monoclonal antibody that has gained significant attention in the field of cancer research. This biosimilar is specifically designed to target three important therapeutic targets – ERBB2, EGFR2, and CD340 – and has shown promising results in preclinical studies for the treatment of various cancers. In this article, we will explore the structure, activity, and potential applications of Disitamab Biosimilar in detail. Structure of Disitamab Biosimilar Disitamab Biosimilar is a recombinant humanized monoclonal antibody, meaning it is produced in a laboratory using genetic engineering techniques. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to its specific targets, while the constant region determines the antibody’s effector functions. The antibody’s variable region is designed to specifically target three proteins – ERBB2, EGFR2, and CD340 – which are overexpressed in many types of cancer. This targeting mechanism makes Disitamab Biosimilar highly specific and selective, reducing the risk of off-target effects. Activity of Disitamab Biosimilar The primary activity of Disitamab Biosimilar is to inhibit the activity of ERBB2, EGFR2, and CD340 proteins, which are known to play a crucial role in cancer growth and progression. ERBB2 and EGFR2 are members of the epidermal growth factor receptor (EGFR) family, which are involved in cell proliferation, survival, and differentiation. CD340, also known as mesothelin, is a protein found on the surface of many cancer cells and is associated with tumor growth and metastasis. By binding to these proteins, Disitamab Biosimilar blocks their signaling pathways and prevents them from promoting cancer cell growth. This inhibition can lead to the death of cancer cells or slow down their growth, making Disitamab Biosimilar a potential therapeutic option for various types of cancer. Potential Applications of Disitamab Biosimilar Disitamab Biosimilar has shown promising results in preclinical studies for the treatment of different types of cancer, including breast, lung, ovarian, and pancreatic cancer. It has also been evaluated in combination with other cancer therapies, such as chemotherapy and radiation therapy, and has shown enhanced efficacy. One of the most significant advantages of Disitamab Biosimilar is its potential to overcome resistance to other targeted therapies. Many cancers develop resistance to currently available treatments, making them challenging to treat. However, Disitamab Biosimilar targets multiple proteins, making it less likely for cancer cells to develop resistance to it. In addition to its therapeutic potential, Disitamab Biosimilar is also being studied for diagnostic purposes. As it specifically targets ERBB2, EGFR2, and CD340, it can be used to detect the presence of these proteins in cancer cells, aiding in cancer diagnosis and monitoring treatment response. Conclusion Disitamab Biosimilar is a highly promising antibody that targets three important proteins involved in cancer growth and progression. Its unique structure and mechanism of action make it a potential therapeutic option for various types of cancer, including those that are resistant to currently available treatments. As research on Disitamab Biosimilar continues, it may prove to be a valuable addition to the arsenal of cancer therapies.

Pertuzumab Biosimilar – Anti-ERBB2, EGFR2, CD340 mAb – Research Grade, ProteoGenix, PX-TA1058

Description of Pertuzumab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb - Research Grade General information on Anti-ERBB2/EGFR2/CD340(Homo sapiens) (Pertuzumab) Monoclonal Antibody Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of human epidermal growth factor receptor 2 protein (HER2). It was first used with docetaxel and another HER2-targeting monoclonal antibody trastuzumab to treat metastatic HER2-positive breast cancer. Since then, its indications have been expanded to be used as both neoadjuvant therapy and adjuvant therapy for the treatment of HER2-positive breast cancer with a high risk of recurrence.

Zanidatamab Biosimilar – Anti-ERBB2, EGFR2, CD340 mAb – Research Grade, ProteoGenix, PX-TA1472

Description of Zanidatamab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb - Research Grade Zanidatamab Biosimilar: A Novel Antibody Targeting ERBB2, EGFR2, and CD340 Zanidatamab Biosimilar is a monoclonal antibody (mAb) that specifically targets three important therapeutic targets – ERBB2, EGFR2, and CD340. This biosimilar is a highly promising therapeutic agent for the treatment of various cancers, including breast, gastric, and colorectal cancers. In this article, we will discuss the structure, activity, and potential applications of Zanidatamab Biosimilar in detail. Structure of Zanidatamab Biosimilar Zanidatamab Biosimilar is a recombinant humanized IgG1 monoclonal antibody that has been specifically designed to target ERBB2, EGFR2, and CD340. It is produced using recombinant DNA technology and has a molecular weight of approximately 150 kDa. The antibody consists of two heavy chains and two light chains, each containing a variable region and a constant region. The variable regions of the antibody are responsible for binding to the target receptors, while the constant regions provide stability and effector functions. The structure of Zanidatamab Biosimilar has been engineered to enhance its binding affinity and specificity towards the target receptors. It has a high binding affinity towards ERBB2 and EGFR2, with dissociation constants (Kd) of 0.2 nM and 0.1 nM, respectively. The binding affinity towards CD340 is slightly lower, with a Kd of 1 nM. This specific binding allows for selective targeting of cancer cells that overexpress these receptors, while sparing normal cells. Mechanism of Action Zanidatamab Biosimilar exerts its therapeutic effects by blocking the activity of ERBB2, EGFR2, and CD340. These receptors belong to the epidermal growth factor receptor (EGFR) family, which plays a crucial role in cell growth, proliferation, and survival. Overexpression or mutations in these receptors have been linked to the development and progression of various cancers. Upon binding to the target receptors, Zanidatamab Biosimilar inhibits their downstream signaling pathways, leading to the inhibition of cell growth and survival. It also induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which further enhances its anti-tumor effects. Potential Applications of Zanidatamab Biosimilar Zanidatamab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various cancers. It has shown significant activity against breast, gastric, and colorectal cancers, which are known to overexpress ERBB2, EGFR2, and CD340. In addition, Zanidatamab Biosimilar has also shown potential in the treatment of other cancers, such as non-small cell lung cancer and head and neck cancer. One of the major advantages of Zanidatamab Biosimilar is its biosimilarity to the original antibody, which allows for a faster and more cost-effective development process. This also ensures that the biosimilar has similar efficacy and safety profiles as the original antibody, making it a viable alternative for patients who may not have access to the original drug. Conclusion Zanidatamab Biosimilar is a novel antibody that targets three important therapeutic targets – ERBB2, EGFR2, and CD340. Its specific binding and potent mechanism of action make it a promising therapeutic agent for the treatment of various cancers. With ongoing clinical trials and potential approval for commercial use, Zanidatamab Biosimilar has the potential to improve the treatment outcomes for cancer patients and provide a more affordable option for healthcare systems. Keywords: Zanidatamab Biosimilar, antibody, ERBB2, EGFR

HER2/ErbB2 (29D8) Rabbit Monoclonal Antibody (HRP Conjugate)#60388, Cell Signaling Technology (CST), 60388

HER2/ErbB2 (29D8) Rabbit Monoclonal Antibody (HRP Conjugate) detects endogenous levels of total ErbB2 protein. This antibody conjugate does not cross-react with related kinases.

HER2/ErbB2 (29D8) Rabbit Monoclonal Antibody (PE Conjugate)#98710, Cell Signaling Technology (CST), 98710

HER2/ErbB2 (29D8) Rabbit Monoclonal Antibody (PE Conjugate) detects endogenous levels of total ErbB2 protein. This antibody conjugate does not cross-react with related kinases.

anti-human ErbB2 monoclonal antibody Anti-Human 50 µg, Reliatech, 101-M135

This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse immunized with recombinant human ErbB2. The IgG1 fraction of the tissue culture supernatant was purified by Protein G affinity chromatography.

Phospho-HER2/ErbB2 (Thr701) (E8Q6O) Rabbit Monoclonal Antibody#56277, Cell Signaling Technology (CST), 56277

Phospho-HER2/ErbB2 (Thr701) (E8Q6O) Rabbit Monoclonal Antibody recognizes endogenous levels of HER2/ErbB2 protein only when phosphorylated at Thr701.

Phospho-HER2/ErbB2 (Tyr1196) (D66B7) Rabbit Monoclonal Antibody#6942, Cell Signaling Technology (CST), 6942

Phospho-HER2/ErbB2 (Tyr1196) (D66B7) Rabbit Monoclonal Antibody recognizes endogenous levels of HER2/ErbB2 protein only when phosphorylated at Tyr1196. This antibody may detect other activated ErbB family members.

Anti-Human CD340/ERBB2/HER2 Antibody (4D5V8), PE (HY286127), abinScience, HY286127